This is in agreement with previous findings using p-tau assays in the same cohort, namely that CSF mid-p-tau181 likely reflects more established tau pathology in Alzheimer’s disease, whereas abnormal levels of N-p-tau181 or N-p-tau217 in early MCI were suggested to have a closer association with initial Aβ changes.20 The gene discussed is MAPT; the disease is Alzheimer disease.